The Myeloma Beacon Results from a small Phase 2 study conducted throughout Japan suggest that a combination of Velcade, doxorubicin, and intermediate-dose dexamethasone is effective in patients with relapsed or refractory multiple myeloma. Most patients (89 percent) ...
The Myeloma Beacon Results from a Spanish Phase 3 study published late Wednesday in the New England Journal of Medicine indicate that treatment of high-risk smoldering m...
Medscape Dexamethasone can reduce cancer-related fatigue in patients with advanced disease and can improve quality of life, but few oncologists use the steroid to mana...
The Myeloma Beacon A new study provides useful, if somewhat dated, insight into the efficacy and safety of Velcade combined with dexamethasone to treat relapsed or refractory multiple myeloma. The retrospective study, which was carried out using data from a single center ...
